We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Universal Health Services Inc. owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers and radiation oncology centers. The company's range of services include general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral health services. The company through its subsidiaries operates inpatient acute care hospitals and behavioral health facilities and outpatient and other facilities. Acute Care - The segment includes inpatient acute care hospitals, free-standing emergency departments and outpatient surgery/cancer care centers and surgical hospital. Behavioral Health Care - The segment includes inpatient behavioral healthcare facilities and outpatient behavioral healthcare facilities, inpatient behavioral healthcare facilities and outpatient behavioral healthcare facilities.
- Recent UHS Stock Price: $102.25
- Yearly Gain for UHS stock: -29.97%
- Market Cap for UHS stock: $6.87B
- P/E Ratio for UHS stock: 9.194
Will UHS's stock price go up? Is there an accurate UHS stock forecast available?
TipRanks.com reports that Universal Health currently has 14 analysts offering 12-month price targets and the consensus is a Moderate Sell rating with an average price target is $121.00. The target pricing ranges from a high UHS forecast of $141.00 down to a low forecast of $90.00. Universal Health (UHS)’s last closing stock price was $102.25 which would put the average price target at 18.34% upside.
In addition, TradingView issued a Sell rating for UHS stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on UHS stock.
Other analysts covering UHS include:
- A.J. Rice of Credit Suisse issued a Buy rating with the price target of $ 141 on 6 days ago
- Ann Hynes of Mizuho Securities issued a Buy rating with the price target of $ 121 on 6 days ago
- Kevin Fischbeck of Bank of America Securities issued a Sell rating with the price target of $ 106 on 6 days ago
- Whit Mayo of SVB Securities issued a Hold rating with the price target of $ 108 on 1 week ago
If you are wondering if UHS is a good stock to buy, here are 3rd party ratings for UHS stock:
- TipRanks.com: Moderate Sell
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 17% (207 out of 251)
What is the sentiment on the street regarding Universal Health? (Current ratings compiled by TipRanks.com)
- News Sentiment for UHS stock: Very Bearish
- Blogger Consensus for UHS stock: Bullish
- Media Buzz for UHS stock: Very High
- Insider Signal for UHS stock: ―
- Investor Sentiment for UHS stock: Positive
- Hedge Fund signal for UHS stock: Negative
The stock market is extremely volatile, and you need to do your own research on UHS stock including scouring the social networks like UHS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for UHS stock chart >>
Summary: CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
- Recent CTMX Stock Price: $1.97
- Yearly Gain for CTMX stock: -66.72%
- Market Cap for CTMX stock: $128.83M
- P/E Ratio for CTMX stock: -1.398
Will CTMX's stock price go up? Is there an accurate CTMX stock forecast available?
TipRanks.com reports that CytomX Therapeutics currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $6.43. The target pricing ranges from a high CTMX forecast of $16.00 down to a low forecast of $1.50. CytomX Therapeutics (CTMX)’s last closing stock price was $1.97 which would put the average price target at 361.93% upside.
In addition, TradingView issued a Buy rating for CTMX stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on CTMX stock.
Other analysts covering CTMX include:
- Joseph Catanzaro of Piper Sandler issued a Hold rating with the price target of $ 1.5 on 12 hours ago
- Peter Lawson of Barclays issued a Buy rating with the price target of $ 3.5 on 12 hours ago
- Robert Driscoll of Wedbush issued a Hold rating with the price target of $ 2 on 12 hours ago
- Kaveri Pohlman of BTIG issued a Buy rating with the price target of n/a on 12 hours ago
If you are wondering if CTMX is a good stock to buy, here are 3rd party ratings for CTMX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 31% (78 out of 251)
What is the sentiment on the street regarding CytomX Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for CTMX stock: Neutral
- Blogger Consensus for CTMX stock: Bullish
- Media Buzz for CTMX stock: Very Low
- Insider Signal for CTMX stock: Positive
- Investor Sentiment for CTMX stock: Positive
- Hedge Fund signal for CTMX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on CTMX stock including scouring the social networks like CTMX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CTMX stock chart >>
Summary: Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
- Recent BPMC Stock Price: $54.28
- Yearly Gain for BPMC stock: -36.59%
- Market Cap for BPMC stock: $3.23B
- P/E Ratio for BPMC stock: -4.925
Will BPMC's stock price go up? Is there an accurate BPMC stock forecast available?
TipRanks.com reports that Blueprint Medicines currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $79.78. The target pricing ranges from a high BPMC forecast of $152.00 down to a low forecast of $40.00. Blueprint Medicines (BPMC)’s last closing stock price was $54.28 which would put the average price target at 46.98% upside.
In addition, TradingView issued a Neutral rating for BPMC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BPMC stock.
Other analysts covering BPMC include:
- David Lebovitz of Citigroup issued a Sell rating with the price target of $ 41 on 6 days ago
- Christopher Raymond of Piper Sandler issued a Hold rating with the price target of n/a on 1 week ago
- Joel Beatty of Robert W. Baird issued a Buy rating with the price target of $ 96 on 1 week ago
- Andrew Berens of SVB Securities issued a Hold rating with the price target of $ 56 on 1 week ago
If you are wondering if BPMC is a good stock to buy, here are 3rd party ratings for BPMC stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 31% (78 out of 251)
What is the sentiment on the street regarding Blueprint Medicines? (Current ratings compiled by TipRanks.com)
- News Sentiment for BPMC stock: Very Bullish
- Blogger Consensus for BPMC stock: ―
- Media Buzz for BPMC stock: Medium
- Insider Signal for BPMC stock: Negative
- Investor Sentiment for BPMC stock: Neutral
- Hedge Fund signal for BPMC stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on BPMC stock including scouring the social networks like BPMC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BPMC stock chart >>
Summary: Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass.
- Recent CDAK Stock Price: $2.77
- Yearly Gain for CDAK stock: -83.77%
- Market Cap for CDAK stock: $62.31M
- P/E Ratio for CDAK stock: -1.832
Will CDAK's stock price go up? Is there an accurate CDAK stock forecast available?
TipRanks.com reports that Codiak BioSciences currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $11.00. The target pricing ranges from a high CDAK forecast of $17.00 down to a low forecast of $7.00. Codiak BioSciences (CDAK)’s last closing stock price was $2.77 which would put the average price target at 297.11% upside.
In addition, TradingView issued a Sell rating for CDAK stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CDAK stock.
Other analysts covering CDAK include:
- David Nierengarten of Wedbush issued a Buy rating with the price target of $ 17 on 1 week ago
- Joshua Schimmer of Evercore ISI issued a Buy rating with the price target of $ 9 on 1 week ago
- Matt Phipps of William Blair issued a Buy rating with the price target of n/a on 1 week ago
- n/a of n/a issued a n/a rating with the price target of n/a on n/a
If you are wondering if CDAK is a good stock to buy, here are 3rd party ratings for CDAK stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 31% (78 out of 251)
What is the sentiment on the street regarding Codiak BioSciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for CDAK stock: Very Bullish
- Blogger Consensus for CDAK stock: ―
- Media Buzz for CDAK stock: Low
- Insider Signal for CDAK stock: ―
- Investor Sentiment for CDAK stock: Neutral
- Hedge Fund signal for CDAK stock: Negative
The stock market is extremely volatile, and you need to do your own research on CDAK stock including scouring the social networks like CDAK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CDAK stock chart >>
Summary: 1Life Healthcare Inc. provides software. The Company offers healthcare application for billing, insurance, planning and other related services. 1Life Healthcare Inc. is based in CA, United States.
- Recent ONEM Stock Price: $10.28
- Yearly Gain for ONEM stock: -67.49%
- Market Cap for ONEM stock: $1.99B
- P/E Ratio for ONEM stock: -5.775
Will ONEM's stock price go up? Is there an accurate ONEM stock forecast available?
TipRanks.com reports that 1Life Healthcare currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $13.00. The target pricing ranges from a high ONEM forecast of $17.00 down to a low forecast of $9.00. 1Life Healthcare (ONEM)’s last closing stock price was $10.28 which would put the average price target at 26.46% upside.
In addition, TradingView issued a Buy rating for ONEM stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ONEM stock.
Other analysts covering ONEM include:
- George Hill of Deutsche Bank issued a Buy rating with the price target of n/a on 1 day ago
- Michael Craig Jones of Stifel Nicolaus issued a Buy rating with the price target of $ 12 on 2 days ago
- Jessica Tassan of Piper Sandler issued a Buy rating with the price target of $ 15 on 1 month ago
- Whit Mayo of SVB Securities issued a Hold rating with the price target of $ 9 on 2 months ago
If you are wondering if ONEM is a good stock to buy, here are 3rd party ratings for ONEM stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Sell, Bottom 45% (138 out of 251)
What is the sentiment on the street regarding 1Life Healthcare? (Current ratings compiled by TipRanks.com)
- News Sentiment for ONEM stock: Neutral
- Blogger Consensus for ONEM stock: ―
- Media Buzz for ONEM stock: Very Low
- Insider Signal for ONEM stock: ―
- Investor Sentiment for ONEM stock: Negative
- Hedge Fund signal for ONEM stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ONEM stock including scouring the social networks like ONEM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ONEM stock chart >>
Summary: Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL.
- Recent VERU Stock Price: $13.02
- Yearly Gain for VERU stock: 71.09%
- Market Cap for VERU stock: $1.04B
- P/E Ratio for VERU stock: -33.449
Will VERU's stock price go up? Is there an accurate VERU stock forecast available?
TipRanks.com reports that Veru currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $28.75. The target pricing ranges from a high VERU forecast of $36.00 down to a low forecast of $24.00. Veru (VERU)’s last closing stock price was $13.02 which would put the average price target at 120.81% upside.
In addition, TradingView issued a n/a rating for VERU stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VERU stock.
Other analysts covering VERU include:
- Kumaraguru Raja of Brookline Capital Markets issued a Buy rating with the price target of $ 31 on 1 day ago
- Chris Howerton of Jefferies issued a Buy rating with the price target of n/a on 1 day ago
- Leland Gershell of Oppenheimer issued a Buy rating with the price target of $ 36 on 4 weeks ago
- Brandon Folkes of Cantor Fitzgerald issued a Buy rating with the price target of $ 24 on 2 months ago
If you are wondering if VERU is a good stock to buy, here are 3rd party ratings for VERU stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 32% (169 out of 251)
What is the sentiment on the street regarding Veru? (Current ratings compiled by TipRanks.com)
- News Sentiment for VERU stock: Neutral
- Blogger Consensus for VERU stock: Bullish
- Media Buzz for VERU stock: Low
- Insider Signal for VERU stock: ―
- Investor Sentiment for VERU stock: Neutral
- Hedge Fund signal for VERU stock: Neutral
The stock market is extremely volatile, and you need to do your own research on VERU stock including scouring the social networks like VERU StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VERU stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================